Vanessa Lucey, PhD, MBA, director of CRI Clinical Accelerator and Venture Fund, speaks on the "Investing into Oncology: Who, What and Where?" (May 5, 1:30–2:45 pm) panel and “Oncology Modalities Facing Off: Room for Many or One to Rule them All?” panel (May 6, 5:45–7:00 pm).
UPDATE: Cancer Progress is going virtual for its 31st Annual Conference.
In light of the ongoing and still evolving novel coronavirus (COVID-19) outbreak, and with the recent announcement by the CDC on the restrictions on gatherings over 50 people, the Cello Health Cancer Progress Committee has made the difficult decision to convert this event to a two-day series of webinars on the original dates in place of the face-to-face event at Convene in New York City. Updates and information will be made as soon as possible.
Since 1989, Cancer Progress invites a discussion of scientific progress within the context of development, regulatory, clinical, commercial and investment perspectives in two days of interactive dialogue. This conference offers pivotal topics, frank discussions, vigorous debate, lively audience participation, and generous networking throughout the meeting during breaks, luncheons, reception, and dinner.
The 31st Annual Meeting on May 5-6, 2020, provides a quality learning experience with experienced speakers, breadth and depth of coverage, and value of professional contacts.
Cancer Progress is organized by Cello Health BioConsulting.
Register at cancerprogressbycellohealth.com.
Photos courtesy of Cello Health BioConsulting
